A major global effort has officially changed the name of a widely misunderstood women’s health condition, previously known as Polycystic Ovary Syndrome (PCOS), to Polyendocrine Metabolic Ovarian Syndrome (PMOS).
The condition affects roughly 1 in 8 women worldwide, amounting to over 170 million people, and has long been misrepresented as being “all about ovarian cysts.
The name change, hailed as a landmark in women’s health, comes after 14 years of international collaboration involving more than 50 patient and professional organizations, including the Endocrine Society.
The move aims to reflect the complex hormonal, metabolic, and reproductive aspects of the condition while eliminating misconceptions that have led to misdiagnoses and inadequate treatment.
From misunderstanding to accuracy:
“What we now know is that there is actually no increase in abnormal cysts on the ovary, and the diverse features of the condition were often unappreciated,” said Professor Helena Teede, Director of Monash University’s Centre for Health Research & Implementation and an endocrinologist at Monash Health.
“For too long, the name reduced a long-term hormonal or endocrine disorder to a misunderstanding about cysts and ovaries,” she added
PMOS is characterized by hormonal fluctuations that impact weight, metabolic and mental health, skin, and reproductive function.
Global, patient-centered effort:
The renaming initiative was a patient-focused process, with over 22,000 survey responses and numerous international workshops involving patients and healthcare professionals.
“This is about accountability and progress,” said Lorna Berry, an Australian woman with PMOS who contributed to the renaming process.
“It’s about my daughters, their daughters, and countless women yet to be born.
Scientific accuracy meets cultural sensitivity:
Piltonen highlighted the importance of cultural sensitivity in the renaming process.
“The new name had to be scientifically correct but also considerate of different cultural contexts,” she said.
Major shift for awareness and treatment:
The initiative is supported by a three-year transition period and a global education and awareness campaign.
Health professionals, governments, and researchers are being informed about the new name, with full adoption expected in the 2028 International Guideline update.
Changing lives, one name at time:
Patients and advocates have expressed relief and hope at the new name.
“The shift to PMOS will help healthcare providers take the condition seriously and improve care for millions of women,” said Teede.
Lorna Berry added, “This is life-changing. Finally, women affected by this condition will see their experiences accurately reflected in the name itself.”
Comments from social media and patient forums echoed the sentiment.
One commenter wrote, “For decades I felt ignored because my doctor focused only on ovarian cysts.
Why the change matters?
It represents a major step toward better healthcare, earlier diagnosis, and improved understanding of a complex condition that affects millions globally.
Misunderstanding the condition previously led to delayed diagnoses and inadequate treatment, often impacting physical, mental, and reproductive health.
The Endocrine society, which supported the effort, highlighted that endocrinologists play a crucial role in addressing pressing health problems including diabetes, obesity, infertility, bone health, and hormone-related cancers.
Looking forward:
The global adoption of PMOS will allow healthcare providers to focus on hormonal, metabolic, and reproductive aspects of the condition, helping millions of women receive the care they need.
Patient led advocacy, international collaboration, and culturally sensitive approaches have all contributed to making this name change a reality.
